
THE EUROPEAN DIRECTORATE FOR THE QUALITY OF MEDICINES & HEALTHCARE (EDQM)















Ph. Eur. Convention


Article 1:

The Contracting Parties undertake:

- a) progressively to ELABORATE a Pharmacopoeia which shall be common to the countries concerned and which shall be entitled "European Pharmacopoeia";
- b) to take the necessary measures to ensure that the monographs which will be adopted... and which will constitute the European Pharmacopoeia shall become the OFFICIAL STANDARDS applicable within their respective countries.

Strasbourg, 22. July 1964

7 ©2020 EDQM, Council of Europe. All rights reserved.



and the R^{ad} Annual Control Section of the Real and the Real Property lines and the R


- Der tr Germannen

Asrell

Unin Pili

LG

edom



International Collaboration

- Ph.Eur.: successful model of work-sharing and harmonisation between currently 39 COUNTRIES, but based on strong political will and legal commitment
- EDQM, USP and the Japanese Pharmacopoeia, with WHO as an observer, are PDG PARTNERS
- Bilateral Agreements/MoUs with pharmacopoeia authorities on COLLABORATION and EXCHANGES (e.g. ANVISA, ChP, PMDA/MHLW, USP, WHO..) and confidentiality arrangements with authorities from around the world
- INVOLVEMENT of observers in the elaboration of texts
- GLOBAL HARMONISATION (Good Pharmacopoeial Practices): EDQM together with PDG partners key player in International Meeting of World Pharmacopoeias (IMWP)

10 ©2020 EDQM, Council of Europe. All rights reserved.
















Different, and even sometimes divergent regulatory environments and constraints, e.g.
 Heparin Case in 2008: PDG pharmacopoeias committed to come up with a harmonised approach, but: regulatory authorities in the three regions not fully aligned, but requesting pharmacopoeia to stay aligned with them
 Proposed policy change on Reporting Threshold in USP–NF Monographs following request by FDA: not aligned between regulators, will create havoc for pharmacopoeial harmonisation, including PDG signed-off texts
•
17 ©2020 EDQM, Council of Europe. All rights reserved.



- Importance of relationship and alignment between REGULATORS, e.g. via ICH, IPRP or bilateral agreements
- Example of the EDQM / Ph. Eur.:
 - One 3rd of Ph. Eur. EXPERTS are from CAs
 - EDQM OBSERVER to QWP, BWP, etc... and vice versa



18 ©2020 EDQM, Council of Europe. All rights reserved.

Different history and working principles
Not much we can do on our HISTORY, but for the rest
Informal PDG process "woven" into the formal processes and committee structures of the three participating pharmacopoeias
 PDG reforms APPROVED in 2017 : Restructuring meeting format to engage more at the technical level and introduce more direct exchange between the experts in the regions. Streamlining of working procedure, reducing complexity => elimination of two stages to increase efficiency and improve focus. Strategic review of harmonization areas and individual work items currently in progress and for future consideration still ongoing. Cleaning of the work programme => identification of items to be considered outside of PDG (e.g. bilateral discussion)
19 ©2020 EDQM, Council of Europe. All rights reserved.





So is there a future for the IMWP?


- An important platform to get to KNOW peers, build TRUST amongst pharmacopoeias, EXCHANGE knowledge and expertise, discuss modes of cooperation....
- Chose a "bottom up" APPROACH: agreed on principles first, e.g. monograph development, TRANSPARENCY, stakeholder CONSULTATION etc., enshrined in "Good Pharmacopoeial Practices"
- Already in place: ALERTING sister pharmacopoeias in case of incidents/crisis, e.g. nitrosamine contamination, to foster application of harmonised (re)action

edom

0

• To be further formalised via Pharmacopoeial Alert System

22 ©2020 EDQM, Council of Europe. All rights reserved.



The Ph. Eur.'s Position

- New chair and vice-chairs ELECTED in 2019 for 3 year mandate
- Presidium (chair, two vice chairs, EDQM director and secretary to the Ph. Eur. Commission) has finalised its **PRIORITIES** for the next 3 years, to be discussed/adopted by the Ph. Eur. Commission in March 2020
- Pharmacopoeial Harmonisation is HIGH on their agenda!



The Ph. Eur.'s Vision
"The Ph. Eur., via its Secretariat, is ACTIVELY engaged in a number of international harmonisation INITIATIVES such as:
 bilateral HARMONISATION efforts with other pharmacopoeias (especially prospective harmonisation of APIs and FPMs);
 Pharmacopoeial Discussion Group (PDG);
 the International Meeting of World Pharmacopoeias (IWMP), a WHO initiative, whose primary ACHIEVEMENT to date is the 'Good Pharmacopoeial Practices' guidelines (GPhP) that will serve as a basis for work-sharing and collaboration between the pharmacopoeias of the world.
In an increasingly globalised world, the need for global quality standards has become ever more pressing. Such NEEDS are regularly expressed by stakeholders, particularly industry, during conferences, for example. International COOPERATION and HARMONISATION will therefore remain a PRIORITY for the next 3 years."
25 ©2020 EDQM, Council of Europe. All rights reserved.

